Angiotensin II is under clinical development by Platform Therapeutics and currently in Phase I for Muscle Spasm.

Talfirastide is under clinical development by Constant Therapeutics and currently in Phase II for Ischemic Stroke.

The dual-action agent LCZ696 blocks the angiotensin II receptor (via a valsartan moiety) and inhibits neprilysin (via an AHU377 moiety). In a phase II trial, this drug “demonstrated superior ...

On the basis of our observations, we reviewed the available literature concerning scar or fibrous tissue production as influenced by angiotensin-converting enzyme, angiotensin II (an important ...